Form 4: Clover Health CEO Reports Routine Stock Vesting

Clover Health's CEO, Medicare Advantage, Jamie L. Reynoso, reported the disposition of Class A Common Stock for tax obligations related to RSU vesting.

Summary

• Jamie L. Reynoso, CEO, Medicare Advantage of Clover Health Investments, Corp. (CLOV), reported two dispositions of Class A Common Stock.
• These dispositions represent shares automatically withheld to cover tax obligations upon the vesting of restricted stock units (RSUs).
• On September 14, 2025, 12,567 shares were disposed of at a price of $3.06 per share, related to RSUs granted on March 14, 2022.
• On September 15, 2025, 8,691 shares were disposed of at a price of $3.14 per share, related to RSUs where vesting occurred on September 15, 2024, from a grant on September 16, 2022.
• Following these transactions, Reynoso beneficially owns 3,058,804 shares of Class A Common Stock.
• The RSUs vest quarterly in equal installments, with final vesting dates on March 14, 2026, and September 16, 2026, respectively, subject to continued service.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to RSU vesting and tax withholding, which are neutral events and do not indicate significant positive or negative sentiment regarding the company's performance or outlook.

Positives

• Continued vesting of restricted stock units indicates the reporting person's ongoing service and alignment with shareholder interests.
• The transactions are routine tax withholdings, not open market sales, suggesting no immediate change in the reporting person's investment thesis.

Negatives

• Disposition of shares, even for tax purposes, reduces the direct beneficial ownership of the reporting person.

Risks

• Continued service of the Reporting Person is a condition for future RSU vesting.

Future Outlook

The remaining restricted stock units (RSUs) are scheduled to vest quarterly in equal installments, with final vesting dates on March 14, 2026, and September 16, 2026, contingent upon the reporting person's continued service.

Industry Context

This routine insider transaction, involving tax withholding upon RSU vesting, is a common occurrence across publicly traded companies, particularly in the healthcare technology sector where executive compensation often includes equity awards. It does not reflect a strategic shift or market sentiment specific to Clover Health beyond the standard compensation practices.

Stakeholder Impact

• Minimal direct impact on shareholders as these are routine tax-related dispositions, not open market sales indicating a change in insider sentiment.
• Employees (specifically the reporting person) are impacted by the vesting schedule and associated tax obligations of their equity compensation.

Next Steps

• Continued quarterly vesting of RSUs granted on March 14, 2022, until the final vesting date of March 14, 2026.
• Continued quarterly vesting of RSUs granted on September 16, 2022, until the final vesting date of September 16, 2026.

Key Dates

Recommendation

This Form 4 filing details routine tax-related dispositions of shares by an executive upon RSU vesting. Such transactions are standard practice for equity compensation and do not reflect a change in the executive's investment conviction or the company's fundamental performance. Therefore, it provides no new information that would warrant a change in an existing investment position; a 'hold' recommendation is appropriate as the filing is neutral in its implications for the stock's future performance.

Keywords

Clover Health, CLOV, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Jamie L. Reynoso, Beneficial Ownership